This is a single-arm, 12-week pilot study evaluating the effects of a chickpea pasta on gut microbiome diversity, gastrointestinal health, and blood biomarkers. The study will involve 12 participants consuming the test product five times per week, with questionnaires, microbiome testing, blood testing, and waist measurements collected at defined timepoints.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
12
The intervention is intended to assess the effects of a high-fiber, legume-based dietary product on gut microbiome diversity, gastrointestinal function, and metabolic biomarkers.
Citruslabs
Las Vegas, Nevada, United States
Change in gut microbiome diversity
Gut microbiome diversity will be assessed using microbiome testing of stool samples. This outcome will evaluate the effect of the intervention on microbial community richness and composition.
Time frame: Baseline and Week 12
Change in gastrointestinal symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
Assessed using the GSRS to evaluate symptoms such as bloating and abdominal discomfort.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in blood biomarkers regarding Hemoglobin A1C
Measured via blood tests including Hemoglobin A1C with eAG.
Time frame: Baseline and Week 12
Change in blood biomarkers regarding CMP-14
Measured via blood tests including CMP-14, lipid panel, and serum iron to assess metabolic and cardiovascular health indicators.
Time frame: Baseline and Week 12
Change in stool quality using the Bristol Stool Scale (BSS)
Assessed using the BSS to evaluate stool consistency and form.
Time frame: Baseline, Week 4, Week 8, and Week 12
Participant-reported perceptions of gut and overall health
Evaluated through self-reported questionnaires on perceived gut health, weight management, bloating, confidence in clothes, and overall well-being.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in waist circumference
Participants will self-measure and report waist circumference to assess changes in central adiposity over the course of the intervention.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline, Week 4, Week 8, and Week 12